Amesite (AMST) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Jun, 2026Executive summary
Annual meeting scheduled for July 13, 2026, to be held virtually, with voting on four key proposals and other business as may arise.
Record date for voting eligibility is May 22, 2026; proxy materials distributed primarily via Internet to reduce costs and environmental impact.
Proposals include director elections, auditor ratification, equity plan amendment, and approval of warrant exercises.
Voting matters and shareholder proposals
Election of two Class II Directors (Ann Marie Sastry and Barbie Brewer) for three-year terms.
Ratification of Novogradac & Company LLP as independent auditor for fiscal year ending June 30, 2026.
Amendment to the 2018 Equity Incentive Plan to increase shares available for issuance and incentive stock options by 1,000,000 each.
Approval of issuance of up to 2,787,464 shares upon exercise of Series A-1 and Series A-2 warrants, including those held by officers and directors.
Board unanimously recommends voting “FOR” all proposals.
Board of directors and corporate governance
Board consists of five directors divided into three classes; majority are independent per Nasdaq standards.
Ann Marie Sastry serves as CEO, President, and Chairman; board leadership structure reviewed periodically.
Committees include Audit, Compensation, and Corporate Governance/Nominating, all with independent members and written charters.
Code of business conduct and ethics and corporate governance guidelines adopted and available on the company website.
Stockholder communications and director nomination procedures detailed for future meetings.
Latest events from Amesite
- Annual meeting seeks approval for director elections, auditor, equity plan, and share issuances.AMST
Proxy filing3 Jun 2026 - Auditors flagged going concern risks; offering led by Laidlaw & Company (UK) Ltd.AMST
Registration filing26 May 2026 - Revenue increased and net loss narrowed, but going concern risks persist despite new capital.AMST
Q3 202618 May 2026 - AI healthcare firm offers 4.8M shares for resale, with viability dependent on warrant exercise proceeds.AMST
Registration filing12 May 2026 - Healthcare AI firm offers shares and warrants to fund growth amid ongoing losses and compliance risks.AMST
Registration filing20 Apr 2026 - NurseMagic™ app drives rapid revenue growth and market adoption in healthcare AI.AMST
Investor presentation6 Feb 2026 - NurseMagic's rapid adoption and scalable AI platform drive strong revenue and market growth.AMST
Investor presentation6 Feb 2026 - Revenue surged but losses persist; going concern and Nasdaq compliance risks remain.AMST
Q2 20266 Feb 2026 - Director and auditor approved; NurseMagic gains traction; strong insider investment.AMST
AGM 202510 Jan 2026